Search Results

The Menarini Group, a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc., a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present updated results from phase 1b/2 ELECTRA and ELEVATE clinical studies evaluating elacestrant in combination with other treatments.

Venatorx Pharmaceuticals and Menarini Group today announced that they have entered into an agreement under which Menarini will acquire the exclusive rights to commercialize, upon approval of relevant health authorities, cefepime-taniborbactam in 96 countries.

Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced the publication, in the Journal of Clinical Chemistry, of the final results of the multicenter DETECT III clinical trial.

The Menarini Group and Stemline Therapeutics, Inc. presented results from phase 1b/2 ELEVATE and ELECTRA clinical studies evaluating ORSERDU® (elacestrant) in combination with other treatments.

The Menarini Group and Stemline Therapeutics, Inc. announced that they have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico’s AI platform, as a potential treatment for hormone sensitive cancers and other oncology indications.

The Menarini Group (“Menarini”), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of the Menarini Group, announced today that they will present new data related to elacestrant in upcoming congresses.

The Menarini Group and Stemline Therapeutics, Inc. announced that they will present new data related to ORSERDU® and ELZONRIS® in two upcoming congresses.

The Menarini Group (“Menarini”) and Stemline Therapeutics, Inc. (“Stemline”), today announced that Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), Stemline’s development partner in Japan, received Orphan Drug Designation for tagraxofusp, from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the expected indication of blastic plasmacytoid dendritic cell neoplasm (BPDCN).